Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

9 treatments under study, led by Shortpulse Nd Yag 1064 Laser

Research Leaders

5 sponsors active, led by Pfizer

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
Phase 1 (1)
Phase 2 (1)

Trial Status

Completed3
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT06980961Not ApplicableRecruitingPrimary

Short and Ultra-short-pulse ND: YAG 1064nm Lasers (Omer Smart and Omer Premium) for Stasis Dermatitis

NCT06427733Phase 1CompletedPrimary

Green Banana Peel Extract for Stasis Dermatitis Treatment

NCT04091087Phase 2CompletedPrimary

Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

NCT03022786Not ApplicableCompletedPrimary

Improving Value of Care for Patients With Severe Stasis Dermatitis

Showing all 4 trials

Research Network

Common Treatments

  • Shortpulse Nd Yag 1064 Laser1
  • Crisaborole1
  • Active Comparator1
  • Cold Cream1
  • Ultrashortpulse Nd Yag 1064 Laser1

Active Sponsors

  • Pfizer2
  • Science Valley Research Institute1
  • Universidade do Vale do Sapucai1
  • University Hospitals Cleveland Medical Center1
  • Ohio Dermatological Association1

Top Investigators

Activity Timeline